Jack Arnold and Rihards Buss preview 6 ACR 2026 abstracts spanning ICI arthritis, PsA proteomics, JAK inhibitor prescribing, and B-cell depletion.
|Slideshows|January 23, 2019
CV Risk in Rheumatic Disease
Author(s)Mark L. Fuerst
(1) Inflammatory diseases raise risk of venous thromboembolism; (2) antiphospholipid antibodies play a role in MI; (3) persistent hyperuricemia predicts mortality.
Advertisement
Advertisement
Related to this article
The FDA approved tildrakizumab for adults with active psoriatic arthritis based on two phase 3 trials showing improved ACR20 response at week 24 vs placebo.
Buss and Arnolds discuss underscore persistent gaps between gout guideline recommendations and real-world practice.
Jessica Gordon, MD, MS, and New York rheumatologists discuss who to screen for ILD, how to monitor without overimaging, and when to add antifibrotics.
Koji Ishikawa, MD, PhD, emphasized that 12 months of romosozumab showed benefits for osteoporosis.
On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Advertisement
Advertisement